Neurocrine Biosciences Inc (NBIX)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands — — — — — — — 169,500 0 0 169,000 377,700 335,100 330,700 326,300 322,000 317,900 425,000 419,500 414,100
Total stockholders’ equity US$ in thousands 2,589,700 2,718,900 2,509,200 2,386,100 2,232,000 2,002,100 1,853,000 1,684,500 1,707,800 1,544,600 1,423,400 1,391,100 1,374,000 1,346,000 1,279,200 1,205,600 1,126,200 804,300 831,200 700,300
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.00 0.12 0.27 0.24 0.25 0.26 0.27 0.28 0.53 0.50 0.59

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,589,700K
= 0.00

The debt-to-equity ratio of Neurocrine Biosciences Inc has shown a decreasing trend over the years, indicating a reduction in the company's reliance on debt financing compared to equity. As of December 31, 2024, the ratio is 0.00, suggesting that the company has no debt obligations in relation to its equity at that point in time. This can be a positive sign, as lower debt-to-equity ratios generally indicate lower financial risk and potentially greater financial stability. It is important to note that a debt-to-equity ratio of 0.00 may also imply that the company may be entirely equity-financed, which could limit its financial flexibility in certain situations. Further analysis would be needed to understand the implications of such a low ratio and its impact on the company's overall financial health and performance.